AMPHASTAR PHARMACEUTICALS IN (AMPH)
US03209R1032 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 201.15M | 144.30M | 156.10M | 126.40M | 92.60M | |||
| Marketable Securities | 88.41M | 112.51M | 19.70M | 10.30M | 13.00M | |||
| Receivables | 138.90M | 115.47M | 89.00M | 78.90M | 66.40M | |||
| Inventories | 115.49M | 105.83M | 103.60M | 92.80M | 96.80M | |||
| Other Current Assets | 11.13M | 11.49M | 10.00M | 9.70M | 10.90M | |||
| Total Current Assets | 555.08M | 489.60M | 378.30M | 318.10M | 279.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 320.39M | 315.64M | 264.60M | 271.50M | 280.70M | |||
| Investments And Advances | 15.16M | 15.21M | 2.40M | 4.00M | N/A | |||
| Goodwill | 3.15M | 3.22M | 3.10M | 3.30M | 3.90M | |||
| Intangibles | 603.91M | 610.08M | 34.20M | 35.60M | 36.70M | |||
| Other Non-Current Assets | 76.62M | 79.16M | 59.40M | 39.10M | 30.20M | |||
| Total Non-Current Assets | 1.02B | 1.02B | 363.70M | 353.40M | 351.50M | |||
| TOTAL ASSETS | 1.57B | 1.51B | 742.00M | 671.50M | 631.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 428.00K | 436.00K | 3.00M | 2.20M | 12.30M | |||
| Accrued Expenses | 212.35M | 197.92M | 66.70M | 70.30M | 74.50M | |||
| Accounts Payable | 36.53M | 25.44M | 20.50M | 22.20M | 24.40M | |||
| Other Current Liabilities | 5.86M | 1.61M | 4.60M | 9.10M | 1.10M | |||
| Total Current Liabilities | 255.17M | 225.41M | 94.90M | 103.80M | 112.20M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 594.01M | 589.58M | 72.80M | 74.80M | 34.20M | |||
| Deferred Taxes/Income | N/A | N/A | 100.00K | 500.00K | 700.00K | |||
| Other Non-Current Liabilities | 52.79M | 58.51M | 45.50M | 46.90M | 35.40M | |||
| Total Non-Current Liabilities | 646.79M | 648.08M | 118.40M | 122.20M | 116.70M | |||
| TOTAL LIABILITIES | 901.96M | 873.49M | 213.30M | 226.00M | 228.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | 452.44M | 409.27M | 271.70M | 180.30M | 117.80M | |||
| Additional Paid In Capital | 476.07M | 486.06M | 455.10M | 422.40M | 410.10M | |||
| Minority Interest | N/A | N/A | 0.00 | -1.20M | 46.70M | |||
| Common Shares | 6.00K | 6.00K | 0.00 | 0.00 | 0.00 | |||
| Treasury Stock | -247.40M | -247.43M | -189.50M | -150.50M | -121.80M | |||
| Other Shareholders' Equity | -8.77M | -8.48M | -8.60M | -6.80M | -3.70M | |||
| Shares Outstanding | 48.84M | 48.07M | 48.10M | 47.70M | 47.50M | |||
| Tangible Book Value per Share | 1.34 | 0.54 | 10.22 | 8.52 | 7.61 | |||
| Total Shareholders' Equity | 672.36M | 639.42M | 528.70M | 445.50M | 402.30M | |||
| TOTAL LIABILITIES AND EQUITY | 1.57B | 1.51B | 742.00M | 671.50M | 631.20M | |||
| Statistics | ||||||||
| Debt/Equity | 0.88 | 0.92 | 0.14 | 0.17 | 0.09 | |||
| Current Ratio | 2.18 | 2.17 | 3.99 | 3.06 | 2.49 | |||
| Return On Assets (ROA) | 9.82% | 9.09% | 12.32% | 9.25% | 0.22% | |||
| Return On Equity (ROE) | 23.00% | 21.51% | 17.29% | 13.94% | 0.35% | |||
| Return On Invested Capital (ROIC) | 12.93% | 12.50% | 13.39% | 9.92% | 1.71% | |||
| Return On Invested Capital Ex Cash (ROICexc) | 16.56% | 15.61% | 18.38% | 13.07% | 2.14% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 40.35% | 38.55% | 19.96% | 14.37% | 2.38% | |||
All data in USD